UK Markets open in 6 hrs 43 mins

Genfit S.A. (GNFT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.6020+0.0520 (+1.14%)
At close: 03:15PM EST
4.7900 +0.19 (+4.09%)
After hours: 04:50PM EST
Full screen
Trade prices are not sourced from all markets
Previous close4.5500
Open4.6020
Bid3.9000 x 4000
Ask4.8900 x 800
Day's range4.6020 - 4.6500
52-week range3.0200 - 5.0500
Volume1,244
Avg. volume12,457
Market cap229.251M
Beta (5Y monthly)1.28
PE ratio (TTM)N/A
EPS (TTM)-3.1400
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

    Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 30, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial. Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the

  • Globe Newswire

    GENFIT Announces 2023 Financial Calendar

    Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 24, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced its provisional financial calendar for 2023. 2023 Financial Calendar February 28, 2023 Publication of revenue and cash position at December 31, 2022 April 13, 2023 Publication of Full Year 2022 financial

  • Globe Newswire

    GENFIT to Participate in Upcoming Investor Conferences

    Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 5, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced that management will participate in upcoming investor conferences. Conference Details (non-exhaustive list): Corporate Access Events during the 41st JPMorgan Healthcare ConferenceDate: January 8 – 12, 202